Lower vs standard radiation dose for low-risk nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests if a slightly lower dose of radiation can work just as well as the standard dose for patients with a certain type of nasopharyngeal cancer. The goal is to reduce side effects while keeping the cancer under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have newly diagnosed nasopharyngeal cancer that has not spread to other parts of the body.
- Your cancer must be the non-keratinizing type (a specific cell type).
- You must be between 18 and 70 years old.
- You must be in good general health (able to do daily activities without help).
- Your blood counts (white cells, platelets, hemoglobin) and liver/kidney function must be within a certain range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a lower dose of radiation to the standard dose for people with early-stage nasopharyngeal cancer. It aims to see if a lower dose is just as effective while reducing side effects.
This trial tests a new way to shape the radiation field for nasopharyngeal cancer that has spread into the nasal cavity. The goal is to reduce radiation to the nose while still effectively treating the cancer.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for nasopharyngeal cancer that has spread to the liver. It aims to see if this approach can help shrink tumors and improve outcomes.
This trial compares a lower dose of radiation to the standard dose for people with advanced nasopharyngeal cancer that shrank after chemotherapy and immunotherapy. The goal is to see if a lower dose works just as well with fewer side effects.
This trial tests whether a smaller radiation treatment area is as effective as the usual larger one for people whose metastatic nasopharyngeal cancer has responded well to first-line chemotherapy plus immunotherapy. It aims to reduce side effects while keeping the cancer under control.
This trial tests whether giving radiation only to the specific lymph nodes that need it works as well as standard radiation for people with nasopharyngeal cancer. It aims to reduce side effects while still controlling the cancer.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.